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Branching morphogenesis of many organs, including the embryonic lung, is a dynamic process in which growth factor mediated tyrosine
kinase receptor activation is required, but must be tightly regulated to direct ramifications of the terminal branches. However, the specific
regulators that modulate growth factor signaling downstream of the tyrosine kinase receptor remain to be determined. Herein, we demonstrate
for the first time an important function for the intracellular protein tyrosine phosphatase Shp2 in directing embryonic lung epithelial
morphogenesis. We show that Shp2 is specifically expressed in embryonic lung epithelial buds, and that loss of function by the suppression
of Shp2 mRNA expression results in a 53% reduction in branching morphogenesis. Furthermore, by intra-tracheal microinjection of a
catalytically inactive adenoviral Shp2 construct, we provide direct evidence that the catalytic activity of Shp2 is required for proper
embryonic lung branch formation. We demonstrate that Shp2 activity is required for FGF10 induced endodermal budding. Furthermore, a
loss of Shp2 catalytic activity in the embryonic lung was associated with a reduction in ERK phosphorylation and epithelial cell proliferation.
However, epithelial cell differentiation was not affected. Our results show that the protein tyrosine phosphatase Shp2 plays an essential role in
modulating growth factor mediated tyrosine kinase receptor activation in early embryonic lung branching morphogenesis.
D 2005 Elsevier Inc. All rights reserved.Keywords: Lung; Shp2; Branching morphogenesis; Erk phosphorylation; Smooth muscle cellIntroduction
Branching morphogenesis is a dynamic process involv-
ing the tight regulation of both positive and negative
signaling molecules. The mouse lung is an excellent model
system for understanding the process of early bud for-
mation. Murine lung development begins at embryonic day
9.5 as a ventral thickening of the primitive foregut. The lung
is formed by a reiterative pattern of elongation and epithelial
cell proliferation in the surrounding mesenchyme. Numer-
ous studies have demonstrated that early epithelial bud
formation is dependent upon cues from the surrounding0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2005.03.022
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1 These authors contributed equally.mesenchyme. Fibroblast growth factor 10 (Fgf10) is a
critical component to early embryonic lung development.
FGF10 is secreted from the mesenchyme and binds to its
cognate receptor FGFR2b in the adjacent epithelium. Fgf10
is responsible for directed outgrowth of the lung endoderm
(Bellusci et al., 1997) and induces cell shape remodeling,
cell migration and proliferation of the adjacent epithelial
cells (Park et al., 1998; Weaver et al., 2002). Although
significant progress has been made in elucidating the role of
growth factor signaling in early lung morphogenesis, the
intracellular signaling molecules that define and regulate
these pathways remain to be established.
The intracellular signaling cascade that regulates FGFR1
signaling has been well characterized. FGFR1 activation
leads to receptor dimerization, activation of tyrosine kinase
activity and autophosphorylation of specific tyrosine resi-82 (2005) 422 – 431
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ing sites for Src homology 2 (SH2)-domain-containing
proteins. Unlike other tyrosine kinase receptors, FGFRs do
not bind Grb2 directly, but require specific docking
proteins to recruit the Grb2/Sos complex upon stimulation.
FRS2 functions as a lipid-anchored-docking protein that
targets signaling molecules to the plasma membrane (Ong
et al., 2000). FGFR activation leads to FRS2 tyrosine
phosphorylation and translocation to the plasma membrane
where the Grb2/Sos complex is recruited. In PC12 cells,
the protein tyrosine phosphatase SHP2 also binds to
phosphorylated FRS2 (Kouhara et al., 1997) and forms a
ternary complex with FRS2 and Grb2 upon FGFR1
activation. The binding of SHP2 amino-terminal SH2
domain to FRS2 is essential for full potentiation of MAP-
kinase activation and FGF-induced neurite outgrowth
(Hadari et al., 1998).
Mammalian Shp2 is a ubiquitously expressed PTPase
that has been characterized as a positive enhancer in the
signal transmission of a variety of growth factors acting
upstream of extracellular signal-regulated kinase (Erk).
SHP2 possesses two tandemly arranged Src homology-2
domains (SH2 domains) in its N-terminus, a phosphatase
domain and two potential Grb2 binding sites in the C-
terminal region. SHP2 is maintained in an inactive state due
to autoinhibition by the N-SH2 domain interacting with the
catalytic site of the PTP domain. The binding of phospho-
tyrosol proteins to the N-SH2 domain of SHP2 results in a
conformational change that allows the protein tyrosine
phosphatase to bind to its substrates (Hof et al., 1998).
SHP2 biological activity requires both the N-SH2 domain
and the phosphatase domain as shown by mutational
analysis (Deb et al., 1998; Feng and Pawson, 1994; Feng
et al., 1993). Maroun et al. (2000) found that overexpressing
a catalytically inactive SHP2 mutant construct into MDCK
cells decreases branching tubulogenesis and inhibits SHP2
sustained ERK activation downstream of the Met tyrosine
kinase receptor.
Analysis of Shp2 mutants indicates that Shp2 activation
is critical to early embryonic development. Shp2 knockout
mice with a targeted mutation in the N-SH2 domain die
during gastrulation as a result of multiple mesodermal
defects (Saxton et al., 1997). The Shp2 chimeric mutant
cells fail to migrate from the primitive streak due to an
impaired chemotactic response to FGF suggesting that Shp2
regulates cell movement in response to tyrosine kinase
receptor signaling (Saxton and Pawson, 1999; Saxton et al.,
2000). Additionally, a comparison of Fgfr1 and Shp2
chimeric mutant limbs indicates that the involvement of
SHP2 in the FGFR1 signal transduction pathway is essential
for limb bud outgrowth.
Shp2 mutant embryos also exhibit phenotypic changes
that are similar to what has been observed in EGFR
knockout mice (Qu et al., 1999). When compound mutants
containing both the Shp2 mutant allele and the Egf-r weak
allele (wa-2) are generated, a defect in cardiac semilunarvalvulogenesis is detected (Chen et al., 2000) indicating a
functional requirement for Shp2 in EGF signaling. An
analysis of the wa-2/wa-2:Shp2+/ embryonic lungs showed
the lungs to be atelectactic with an increase in thickness and
cell mass of the alveolar septa.
The function of Shp2 during lung epithelial bud
formation and epithelial cell proliferation has yet to be
fully investigated. Thus, for the first time, we provide
evidence demonstrating the requirement for Shp2 activity
during embryonic lung organogenesis. By two compli-
mentary approaches, we show that a loss of Shp2 activity
results in a decrease in embryonic lung branching
morphogenesis and a decrease in FGF10 stimulated
endodermal budding. Finally, we observe that Shp2
catalytic activity is required for Erk phosphorylation
and epithelial cell proliferation but not for cell
differentiation.Materials and methods
Organ culture
Embryonic day 11.5 (E11.5) lungs were removed and
placed on MF-Millipore filter disks. The disks were then
placed on a stainless steel mesh and cultured in a chemically
defined medium: BGJb (GIBCO, Grand Island, NY) with
0.1 mg/ml ascorbic acid and 50 units/ml penicillin and
streptomycin. Lung explants were cultured for 2–4 days
with the medium changed every 2 days.
Primary mesenchymal cell isolation
Embryonic day 13.5 (E13.5) lungs were removed and
placed in 1 ml of 0.025% Trypsin (GIBCO, Grand Island,
NY) for 10 min at 37-C. Following trypsin digestion, lung
rudiments were passed through 19.5–27.5 gauge needles.
Cells were then blocked with DMEM 10% serum, and
plated on 60 mm dishes for 1 h at 37-C to let the
mesenchymal cells adhere. The cells were then washed 10
times to remove any floating cells. Cells were grown for
48 h to 72 h in DMEM + 10% fetal bovine serum
(GIBCO, Grand Island, NY) and then harvested for
Western blot analysis.
Endodermal isolation
Lungs were isolated from E12.5 embryos and treated
with dispase 50 U/ml for 1 h at 4-C. The lungs were
transferred to DMEM/F12 with 10% FBS. The endoderm
was micro-dissected using tungsten needles and transferred
into fresh DMEM/F12 with 10% FBS. Subsequently, the
endoderm was infected with either Ad-Shp2WT or Ad-
Shp2RM. The endoderm was grown in growth factor
reduced Matrigel\ with 500 ng/ml FGF10 (R&D Systems)
in DMEM/F12.
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Microdissected lungs were fixed in 4% paraformalde-
hyde in phosphate-buffered saline (PBS) for 2 h. They were
washed twice with PBS and dehydrated overnight in 70%
ethanol at 4-C. Whole mount in situ hybridization was
performed as previously described (Mailleux et al., 2001).
The following mouse cDNAs were used as templates for the
synthesis of digoxigenin-labeled riboprobes: a 938 bp
mouse Shp-2 cDNA and a 548 bp Fgf10 cDNA (Bellusci
et al., 1997).
Sequence of Shp2 antisense and sense ODNs
Antisense oligodeoxynucleotides (ODN) were designed
around the translational start site of Shp2 (Genbank no.
D84372). In addition, two same length oligonucleotides
were designed to use as controls. The oligonucleotides were
added separately to the culture medium at a final concen-
tration of 30 AM. The oligonucleotides used were: Shp2
antisense (ODN) 5V-TCTCCG CGATGTCATGT-3V; sense
ODN 5V-ACATGACATCGCGGAGA-3V; scrambled ODN
5V-GTTACTGCATTCCTGC-3V.
Branching morphogenesis
Lung branching morphogenesis was determined by
counting the number of epithelial sacs around the periphery
of the lung explants. Transillumination and photomicro-
graphy were used to detect structures and record permanent
images. Six to eight lungs were counted per data point and
statistical significance was determined by ANOVA and t test
(criterion for significance was P < 0.05).
Competitive RT-PCR quantification
Competitive RT-PCR methodology was used to deter-
mine the effects on mRNA levels in treated lungs, as
previously described (Zhao et al., 1998). Briefly, the same
primers for mouse Shp2 were used to amplify both the
cDNA and competitor for each gene of interest. The
upstream primer for cDNA synthesis was 5V-TGTGAG-
GACTGTGGCAAGTGC-3V and the downstream primer
was 5V-TTTAAGGCAACCCTTGCTGG-3V resulting in a
300 bp PCR product. Two composite primers were
synthesized to construct the Shp2 competitor. Each set of
composite primers contained the Shp2 sequence as well as a
short sequence designed to hybridize to the cDNA of
interest. This allowed the incorporation of the Shp2
sequence into the DNA during PCR. The competitor now
had the same primer sequence as the Shp-2 cDNA. The
DNA used for the competitor was v-erbB DNA. The
competitor was then sequenced to verify the incorporation
of the gene-specific primers and was 400 bp long. The same
primers were used to amplify 1 fg of competitor and scaled
concentrations of cDNA. The log of cDNA/competitor wasplotted against the target concentrations producing a
coefficient r2 > 0.98 (data not shown). The same assay
was developed for other genes used in this publication.
Competitive PCR quantitation allows the accurate assess-
ment of mRNA levels and is reliable without contaminating
DNA species.
Quantitation of cDNA
Target cDNA and competitor PCR products were
separated by electrophoresis on a 3% agarose gel (3:1
mixture of Nusieve and Seakem; FMC, Rockland, ME). The
gel was run in a submarine gel apparatus (C.B.S. Scientific
Co., Del Mar, CA) and stained with 5 Ag/ml ethidium
bromide. Photographs were taken and the intensity of the
bands was determined by densitometry. Calculations were
performed with Microsoft Excel 5.0 and significance was
determined P < 0.05. All data are expressed as the mean T
SD. All experiments were repeated at least three times.
Recombinant adenovirus intra-tracheal microinjection
Three adenoviral vectors were used in this study: full
length SHP-2 (Ad-SHP2WT), catalytically inactive mutant
of SHP2 (Ad-SHP2RM) and a control vector containing the
GFP cDNA (kind gifts from Dr. Anton Bennett). Adeno-
viral intra-tracheal microinjection was performed as pre-
viously described (Mailleux et al., 2001).
Histology and immunohistochemistry
Cultured lungs (72 h) were fixed in 4% paraformalde-
hyde for 20 min, washed in PBS, dehydrated and paraffin
embedded. Sections were treated with: a monoclonal anti-a-
smooth muscle actin, clone 1A4, Cy3 conjugated antibody
at 1:200, and anti-Sp-C polyclonal antibody dilution 1:1000
(a kind gift of Dr. Jeffrey Whitsett). Phospho-Erk was
detected using the phospho-p44/42 MAPK (20G11; Cell
Signaling). All slides were mounted with DAPI containing
Vectashield and photomicrographs were taken.
Cell proliferation assay
For BrdU labeling, lungs were cultured in the presence of
monoclonal anti-bromo-deoxyuridine (1:50, Sigma) for 45
min prior to harvesting. BrdU positive cells and total
number of cells were counted in 5 randomly selected areas
per each sample. Statistical significance was determined at a
P value less than 0.05.
Western blot analysis
Mouse lung tissues were lysed in ice-cold RIPA buffer
(1% Triton X 100, 0.5% NP40, 150 mM NaCl, 10 mM Tris
pH 7.4, 1 mM EDTA, 1 mM EGTA, 100 mM NaF, 1 mM
orthovanadate, protease inhibitor cocktail). Total protein
Fig. 1. Shp2 expression in the lung epithelium. Whole mount in situ
hybridization in E14.5 lung explants and SHP2 protein expression in mouse
lung epithelial cells (A–B). (A) Shp2 is highly expressed in the distal lung
epithelium with a minimal detection observed in the more proximal
epithelial airways. In contrast, Fgf10 expression is localized to the
embryonic lung mesenchyme. (B) Western blot analysis of SHP2 protein
expression shows SHP2 to be expressed in the whole lung and mouse lung
epithelial cells while no detection is observed in primary mesenchymal cell
cultures. (C) Western blot analysis demonstrating that Shp2 is tyrosine
phosphorylated in response to FGF10 stimulation.
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ferred onto polyvinylidene difluoride (PVDF) membranes
(Millipore, Bedford, MA). The membranes were blocked
with 1% blocking solution (Roche Molecular Biochem-
icals, IN) and incubated overnight at 4-C with anti-SHP2
(Santa Cruz) or h-actin diluted at 1:2500. The phospho-
tyrosine antibody (RC20; Transduction Laboratories) was
used at a concentration of 1:1000. Unbound antibody was
washed 4  10 min followed by incubation with either
goat anti-rabbit IgG:horseradish peroxidase (1:20,000) or
goat anti-mouse IgG HRP (1:10,000) secondary anti-
body for 30 min. Membranes were washed 4  15
min and binding was detected using the enhanced
chemiluminescence method (Roche Molecular Biochem-
icals) and XAR-5 film (Eastman Kodak, Rochester
NY). All experiments were repeated at least three to
four times, with similar results obtained within repetitive
experiments.
Immunoprecipitations
Mouse lung epithelial cells were starved in DMEM for
18 h prior to FGF10 stimulation (R&D). Cells were either
left untreated or stimulated with FGF10 (250 ng/ml) for 5
and 10 min followed by 3 washes of cold 1 PBS and
addition of RIPA lysis buffer. Clarified cell lysates were
immunoprecipitated with Shp2 antibody overnight at 4-C
followed by three washes with lysis buffer. SDS-sample
buffer was added, and the immune complexes were
separated as described above.
Statistical analysis
Calculations were performed using Microsoft Excel 5.0.
Significance was determined by ANOVA and t test with
criterion set at P < 0.05. All data were expressed as mean T
standard deviation (SD).Results
Shp2 expression and phosphorylation in response to FGF10
signaling
To begin to investigate the role of Shp2 during
embryonic lung branching morphogenesis, we performed
whole mount in situ hybridization to determine Shp2
expression pattern. At E14.5, Shp2 is expressed at high
levels in the distal epithelium at the periphery of each lung
lobe (Fig. 1A). A low level of Shp2 expression is also
detected in the more proximal airways, an expression
pattern that is similar to Fgfr2. Fgf10 expression pattern
was also determined to show a comparison between
epithelial and mesenchymal cell expression since Fgf10
expression is known to be specifically restricted to the lung
mesenchyme.To illustrate further that Shp2 is only expressed in the
mouse lung epithelial cells, we used Western analysis.
SHP2 protein expression was detected in whole lung
tissue and mouse lung epithelial cells (MLE12). However,
we found no detection of SHP2 expression in lung
primary mesenchymal cells (Fig. 1B). h-actin was used
to ensure equal loading for Western analysis. Together,
these results demonstrate that SHP2 expression is specif-
ically restricted to the distal part of the embryonic lung
epithelium.
We have previously shown that SHP2 disassociates
from mSprouty2 upon FGF10 stimulation (Tefft et al.,
2002). Thus, we considered the possibility that SHP2
may be tyrosine phosphorylated downstream in the
FGF10 signaling pathway. Fig. 1C illustrates that SHP2
is indeed tyrosine phosphorylated upon FGF10 stimula-
tion at both 5 and 10 min, suggesting that Shp2 functions
within the FGF10 tyrosine kinase receptor signaling
pathway.
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morphogenesis
To support our hypothesis that Shp2 functions as a
positive regulator in embryonic mouse lung development,
we used antisense oligodeoxynucleotide (ODN) techno-
logy to decrease endogenous Shp2 mRNA expression.
E11.5 lungs were cultured for 4 days in the presence of
either 30 AM Shp2 antisense (AS) ODNs, 30 AM of Shp2
sense (Sen) ODNs or in a known serum free chemically
defined medium that allows for spontaneous branching
morphogenesis. Shp2 antisense treated lungs displayed
impaired embryonic lung branching morphogenesis com-
pared to sense or media control lungs (Fig. 2A).
Quantitative analysis of E11.5 lungs cultured in the
presence of 30 AM antisense Shp2 ODN showed a
significant decrease in branching morphogenesis (Fig. 2B)
when compared to the sense or media control lungs (53% of
media control, P < 0.05).
Competitive RT/PCR analysis was used to assess
changes in gene expression in cultured lung explants. As
shown in Fig. 2C, only lungs treated in the presence of 30
AM Shp2 antisense ODNs and not sense or media control
lungs had a significant decrease in endogenous Shp2 mRNA
expression (96% of media control, P < 0.05). Additionally, a
decrease in both TTF-1 and Sp-C mRNA expression is
detected in Shp2 antisense treated lungs (41% and 53%
respectively, P < 0.05). Since both Sp-C and TTF-1 act as
epithelial/maturation markers our findings suggest that Shp2
activity is required for proper formation and maturation of
the developing mouse lung.Fig. 2. Shp2 antisense oligonucleotide strategy in E11.5 cultured lungs. Quantitativ
sense oligonucleotides (ODNs), 30 AM Shp2 antisense (AS) ODNs or in a chemi
branching compared to Shp2 sense (Sen) and control lungs. (C) Antisense Shp2
measured by competitive RT/PCR.Histological examination of Shp2 antisense treated lungs
Hematoxylin and eosin (HE) staining of lung specimens
was used to examine morphological changes in lungs treated
with Shp2 antisense ODNs.
Lungs cultured in the presence of 30 AM Shp2
antisense ODNs displayed less tightly packed distal
airways with an increase in cell density between them
compared to the media controls (Figs. 3A–C). Impaired
branch formation was also observed in Shp2 antisense treated
lungs (Fig. 3D).
Overexpression of a catalytically inactive SHP2 adenoviral
mutant construct inhibits epithelial branching
morphogenesis
SHP2 catalytic activity is required for full potentiation
of Erk activation and epithelial morphogenesis down-
stream of the Met tyrosine kinase receptor (Maroun et al.,
2000). Therefore, to determine the biological effect of
SHP2 activity during embryonic lung epithelial morpho-
genesis, we introduced a catalytically inactive SHP2
mutant adenoviral construct (Ad-SHP2RM) fused to a
GFP tag into E12 lung epithelium by intra-tracheal
microinjection. Intra-tracheal microinjection of Ad-
SHP2RM into E12 lungs exerted an inhibitory effect on
lung morphogenesis (Fig. 4C) when compared to lungs
overexpressing SHP2 wild-type or media control lungs
(Figs. 4A and B). The distal airways appeared to be
severely dilated a phenotype that was also observed in
the Shp2 antisense treated lungs. Branching morpho-e analysis of lungs cultured for 4 days in the presence of either 30 AM Shp2
cally defined media (A–B) Shp2 antisense significantly decreased terminal
also decreased specific epithelial/maturation markers, Sp-C and TTF-1, as
Fig. 3. Histology of Shp2 antisense treated lungs. Hematoxylin and Eosin staining of Shp2 antisense treated lungs. (C–D) Lungs cultured in the presence
of Shp2 antisense ODNs have less tightly packed distal airways with an increase in cell density between the alveoli compared to media control (MC)
lungs (A–B).
Fig. 4. Overexpression of a catalytically inactive SHP2 adenoviral mutant construct inhibits epithelial branching morphogenesis. The intratracheal
microinjection of a catalytically inactive SHP2 adenoviral construct, Ad-SHP2RM, inhibited lung branching morphogenesis (C) when compared to lungs
overexpressing Ad-SHP2WT construct or media control lungs (A–B). (D) A significant decrease in terminal branching was observed in Ad-SHP2RM
microinjected lungs ( P < 0.05). (E) Western blot analysis of whole lungs demonstrates successful overexpression of the SHP2 adenoviral constructs. (F–G)
Competitive RT/PCR analysis of adenoviral microinjected lungs. A significant reduction in Sp-C and TTF-1 mRNA expression is observed in Ad-SHP2RM
overexpressing lungs.
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when compared to microinjected Ad-SHP2WT and media
control lungs (Fig. 4D; P < 0.05).
To demonstrate that we successfully overexpressed the
adenoviral constructs into the lung, we used Western blot
analysis as well as direct detection of GFP in the infected
lungs. As demonstrated in Fig. 4E, a high level of GFP was
detected in the adenoviral treated lungs whereas no
detection of GFP was observed in media control lungs.
Quantitative RT/PCR analysis was performed on the
microinjected lungs to determine changes in gene expres-
sion when SHP2 catalytic activity is lost. As previously
found, a loss of SHP2 activity due to the overexpression of
the catalytically inactive Ad-SHP2RM construct reduced
both Sp-C and TTF-1 mRNA expression (Figs. 4F and G;
75% and 63% respectively, P < 0.05).
Catalytically inactive Shp2 reduces FGF10 stimulated
endodermal bud formation
We have previously shown that Fgf10 is responsible for
directed outgrowth of the lung endoderm (Bellusci et al.,
1997). Therefore, we decided to investigate the role of Shp2
in FGF10 stimulated endodermal bud formation. E12
isolated endoderm soaked in the AdHSHP2-RM virus
showed a reduction in FGF10 stimulated endodermalFig. 5. Catalytically inactive SHP2 inhibits FGF10 stimulated endodermal branchin
ml FGF10. (A–C) At 24 h and 48 h, the control lungs and the AdSHP2-WT (D
catalytically inactive Shp2 mutant virus (AdSHP2-RM) shows a lack of buddingoutgrowth compared to AdSHP2-WT or control lungs
(Fig. 5). In control and AdSHP2-WT soaked endoderm
there was endodermal swelling at 24 h when embedded in
matrigel containing FGF10. At 48 h, FGF10 endodermal
cultures began to show extensive budding. However, lungs
soaked in AdSHP2-RM displayed a marked reduction in
FGF10 induced budding with irregularly shaped primary
buds finally appearing at 48 h.
Impaired function of SHP2 decreases Erk phosphorylation
and a-smooth muscle actin expression
Immunohistochemistry was performed on SHP2 adeno-
viral treated lungs to determine the impact of SHP2 on
epithelial cell cytodifferentiation and Erk phosphorylation in
lung development. SHP2 has been implicated as a positive
regulator of Erk activation in multiple RTK signaling
pathways. Therefore, to demonstrate the involvement of
SHP2 activity on Erk activation in the mouse embryonic
lung, we used antibodies specific for the phosphorylated
forms of Erk1 and Erk2. In media control lungs, a strong
detection of Erk phosphorylation was observed in the
epithelium of the developing lung (green). A minimal
amount of Erk phosphorylation was detected in the
surrounding mesenchyme. The same pattern of Erk phos-
phorylation was also observed in lungs overexpressing theg. Embryonic lung endoderm was embedded in Matrigel containing 250 ng/
–F) lungs undergo extensive budding. (G– I) Endoderm treated with the
at 24 h and a minimal amount of irregular endodermal budding.
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the other hand, overexpression of the catalytically inactive
SHP2 construct (Ad-SHP2RM) resulted in a considerable
reduction of epithelial Erk phosphorylation by 62% (Fig. 6C,
P < 0.05). There was no difference in mesenchymal cell Erk
phosphorylation between wild-type and mutant Shp2 lungs.
Since a-smooth muscle actin is a marker for mesen-
chymal cell differentiation, we examined the expression of
a-smooth muscle actin in our microinjected treated lungs. In
both the media control (MC) and Ad-SHP2WT lungs, there
is a high level of SMA expression (red) in the most
proximal mesenchymal region and epithelial basement
membrane and a diffuse level of expression in the more
distal mesenchyme (Figs. 6D–F). However, in the lungs
expressing the catalytically inactive SHP2 mutant construct
(Ad-SHP2RM), there was only a slight detection of SMA
expression in the proximal epithelial basement membrane
and no detection of SMA expression was observed in the
distal mesenchyme.
Reduced level of epithelial cell proliferation in SHP2
adenoviral treated lungs
Next, we tested the possibility that a loss of Sp-C
expression could be accompanied by a defect in epithelial
DNA synthesis. Therefore we used BrdU labeling to detect
changes in cell proliferation, stained in red (Fig. 7). TheFig. 6. Impaired function of SHP2 decreases Erk phosphorylation. Immunohistoche
(MC) lungs. Phospho-Erk and Sp-C were analyzed by immunohistochemistry (g
overexpression of Ad-SHP2WT lungs (B) show a strong detection of Erk phosp
resulted in a clear reduction in epithelial Erk phosphorylation. (D–E) Both the me
BGJB showed numerous Sp-C positive cells in the distal epithelium. (F) Lungs m
positive cells and a clear reduction in Sp-C expression in the distal epithelium. (A–
lungs microinjected with the catalytically adenoviral mutant construct Ad-SHP2Rproliferation rate in the pulmonary epithelial cells was
decreased by 57% in lungs overexpressing the SHP2
dominant negative construct (Ad-SHP2RM; P < 0.05)
whereas there was no change in mesenchymal cell prolifer-
ation. This data suggests that SHP2 catalytic activity is
required for early pulmonary epithelial morphogenesis.Discussion
Our present study provides novel insight into the
regulation of lung epithelial branching morphogenesis. We
show that the protein tyrosine phosphatase Shp2 is
specifically expressed in the mouse embryonic distal lung
epithelium. We also provide direct evidence by two
complementary but separate approaches that a loss of
SHP2 activity decreases lung branching morphogenesis
and epithelial Erk phosphorylation. Furthermore, the over-
expression of a catalytically inactive SHP2 mutant construct
reduces epithelial cell proliferation, and a-smooth muscle
actin expression. Taken together, these results indicate that
Shp2 plays an essential role during the early stages of
embryonic lung organogenesis.
Tyrosine phosphorylation of growth factor receptor
kinases induces recruitment and activation of downstream
signaling molecules leading to multiple signaling events.
Shp2 is the orthologue of Drosophila Csw, which wasmistry was performed on SHP2 adenoviral microinjected and media control
reen); nuclei were stained with DAPI (blue). Both media control (A) and
horylation in the epithelium (arrows). (C) Overexpression of Ad-SHP2RM
dia control E12 and Ad-SHP2WT microinjected lungs cultured for 4 days in
icroinjected with Ad-SHP2RM displayed only patchy distribution of Sp-C
F) a-smooth muscle actin, shown in red, was also reduced in the embryonic
M compared to media control and Ad-SHP2WT lungs. MC: media control.
Fig. 7. Reduced level of epithelial cell proliferation in SHP2 adenoviral treated lungs. BrdU labeling, stained in red, was performed on media control and
adenoviral microinjected lungs. (C–D) Epithelial cell proliferation was significantly reduced in the Ad-SHP2RM treated compared to MC (A) and Ad-
SHP2WT (B) lungs.
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kinase signaling. Preliminary functional analysis of Droso-
phila Csw demonstrated that Csw operates as a positive
regulator downstream of multiple tyrosine kinase receptors
including the fibroblast growth factor receptor orthologue
Breathless (Perkins et al., 1996). In Drosophila trachea
placode development, Branchless, the Fgf10 orthologue and
main controller of trachea branching, binds to Breathless
inducing both primary and secondary branching. Hence, this
suggests that Csw functions as a downstream regulator in
the Branchless/Breathless signaling pathway.
We have previously demonstrated that upon FGF10
stimulation of mouse lung epithelial cells, SHP2 disasso-
ciates from mSprouty2, a known inhibitor of the FGF10
MAP-kinase signaling pathway (Tefft et al., 2002). Since
Fgf10 is a key regulator of mouse embryonic lung bud
formation (Bellusci et al., 1997), we tested the possibility
that SHP2 functions downstream in the FGF10 tyrosine
kinase receptor pathway. We found Shp2 to be tyrosine
phosphorylated upon FGF10 stimulation. Furthermore,
Shp2 catalytic activity is required for FGF10 induction of
endodermal bud formation. This then would suggest that
Shp2 functions as a positive regulator within the FGF10
signaling pathway, and that the function of Shp2 is
evolutionary conserved.
Shp2 chimeric mutant mice display multiple develop-
mental defects signifying the critical role for Shp2 in
organogenesis. The neonatal mice that survive have
difficulty breathing and their lungs are found to be hypo-
plastic with hypercellular thickened alveolar walls (Qu et
al., 1998). Using an adenoviral intra-tracheal microinjectiontechnique to overexpress a catalytically inactive SHP2
mutant into embryonic day 12 lungs, we demonstrated that
SHP2 is required for the early stages of murine lung
branching morphogenesis. A similar finding of the require-
ment for SHP2 catalytic activity has been documented in
kidney tubulogenesis (Rosario and Birchmeier, 2003). In
addition, the catalytic activity of SHP2 was necessary for
sustained Erk MAP-kinase activation (Maroun et al., 2000).
We observed that the overexpression of a catalytically
inactive SHP2 mutant construct decreased epithelial Erk
phosphorylation, epithelial cell proliferation. Sp-C expres-
sion is associated with epithelial cell differentiation and
TTF-1 is used as a general marker of epithelial cells during
the pseudoglandular stage. In the event of a specific
differentiation defect triggered by the expression of the
catalytically inactive Shp2, we would expect that TTF-1 and
Sp-C mRNA levels would be significantly different in
catalytically inactive Shp2 mutant lungs to determine
cellular differentiation. However, since both TTF-1 and
Sp-C mRNA levels were not significantly different, we
conclude that Shp2 catalytic activity is required for
epithelial cell proliferation and not for differentiation.
In summary, this is the first study to demonstrate a
function for the protein tyrosine phosphatase Shp2 in early
embryonic lung branching morphogenesis. Our data reveals
that the catalytic activity of SHP2 is required for Erk
phosphorylation, FGF10 induction of endodermal bud
formation and epithelial cell proliferation. Currently, we
are investigating the molecular mechanisms of Shp2 action
downstream in the FGF10 tyrosine kinase receptor signaling
pathway. Since un-regulated FGF signaling has been
D. Tefft et al. / Developmental Biology 282 (2005) 422–431 431implicated in developmental defects and in cancer, identify-
ing the biological function of Shp2 downstream the FGF
tyrosine kinase signaling pathway may provide clues for
designing new therapeutic tools.Acknowledgments
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